Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

2nd CRISPR Congress Boston, 23-25 February 2016

The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.

  • Soyez le premier à commenter

  • Soyez le premier à aimer ceci

2nd CRISPR Congress Boston, 23-25 February 2016

  1. 1. February 23-25 2016 | Boston, USA • Improve Target Specificity & Efficiency of Genome Editing • Enhance Drug Discovery & Screening Applications • Design & Develop Clinical Therapies 2nd Annual Rachel Haurwitz Caribou Biosciences Jon Moore Horizon Discovery Alexandra Glucksmann Editas Medicine Emmanuelle Charpentier Max Planck Institution, Umeå University George Church Harvard Medical School Rodger Novak CRISPR Therapeutics This is designed to describe the profound impact CRISPR is having on basic research and therapeutic development. It will explore the research tools, bioinformatics and expertise needed to make the most of this breakthrough technology. Eric Rhodes, Horizon Lead Partner Additional Event Partners Tel: +1 212 537 5898 | Email: info@hansonwade.com RESEARCHED & DEVELOPED BY:crispr-congress.com
  2. 2. Welcome to Those Dedicated to CRISPR 2.Engineer the next generation of humanized animal models cell lines for improved disease modeling and preclinical predictability 2. Harness CRISPR technology for more accurate gene editing in non-eukaryotic  bacterial and plant cells 5 Key Benefits to Takeaway 1. Discover innovative ways to measure and optimize specificity of the CRISPR/Cas9 system in order to reduce off target effects 1. Effectively adopt the lentiviral delivery system to optimize genome wide targeting from basic research to drug discovery 3. Develop strategies to perform large scale genome wide screening from basic research to disease target identification 3.Utilize CRISPR/Cas9 to develop robust cell- based cancer immunotherapies including CAR-Ts and TCRs 4. Learn how to independently design and optimize CRISPR with novel emerging enzymes (Cpf1) to enhance the precise nature of genome editing 4. Understand the regulatory requirements for CRISPR/Cas9 mediated therapeutic development as it is poised to demonstrate clinical utility 5.Enhance the delivery and efficiency of  CRISPR/Cas9 in primary cells 5.Harness CRISPRi to elevate the regulation of gene expression through epigenetic modifications 5 Key Ideas to Implement Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 Achieve the Full Potential of CRISPR Genome Editing to Ensure Accuracy Success Optimize your CRISPR Design to Efficiently Power Novel Applications in Drug Discovery, Screening and Therapeutic Development The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome. With the superior applications of CRISPR showing no signs of relenting, join the leading CRISPR figureheads as they reveal advanced methodology, strategies and clinical timelines that maximize the power of precision genome editing and fulfill its revolutionary potential.  As well as applying CRISPR to optimize the custom development of stable cell lines disease models for target identification and enhanced drug discovery, CRISPR Congress 2016 pioneers the translation of CRISPR-based gene therapies into a clinically relevant transformative therapy. As CRISPR continues to create a sea change for genetic research, not to mention the next class of enzymes on the horizon, join the CRISPR Congress to deepen your understanding, minimize off-target effects and elevate delivery mechanisms for therapeutic use. There is a a key opportunity for you to network and build future collaborations with fellow peers to  optimize the application of CRISPR gene editing technology and transform your research to the next level. Why the 2nd CRISPR Congress Should Be in Your Calendar
  3. 3. Speaker Faculty 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing Rachel Haurwitz President CEO Caribou Biosciences Alexandra Glucksmann Chief Operating Officer Editas Medicine Emmanuelle Charpentier Director Max Planck Institution for Infection Biology, MIMS Umeå University George Church Professor of Genetics Harvard Medical School Jon Moore CSO Horizon Discovery John Feder Associate Director of Genome Biology Bristol-Myers Squibb TJ Cradick Head of Genome Editing CRISPR Therapeutics Joel Klappenbach Director of Applied Genomics Merck Gregory Davis RD Manager, Molecular Biotechnology Sigma-Aldrich Charles Gersbach Associate Professor, Director, Center of Biomolecular Tissue Engineering Duke University David Root Senior Director, Broad Institute Genetic Perturbation Platform and the Functional Genomics Consortium Channabasavaiah Gurumurthy Assistant Professor- Genetics, Director- Mouse Genome Engineering Core Facility, University of Nebraska Medical Center Greg Gocal Senior Vice President RD Cibus Benjamin Kleinstiver Postdoctoral Fellow, Keith Joung’s Group, Massachusetts General Hospital Harvard Medical School   Lorenz Mayr VP Global Head, Reagents Assay Development AstraZeneca John Doench Associate Director, Genetic Perturbation Platform, MIT Harvard University   Jennifer Berman Staff Scientist, Applications, Digital Biology Center Bio-Rad Laboratories Rodger Novak Chief Executive Officer CRISPR Therapeutics Jonathan Gootenberg Feng Zhang’s Lab, Broad Institute, MIT Harvard University   Jason Potter Senior Scientist Manager Thermo Fisher Scientific Shawn Zhou Senior Scientist Genscript Wen Xue Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Anja Smith Director of RD Dharmacon, GE Healthcare Mark Behlke, Chief Scientific Officer Integrated DNA Technologies, Inc Daniel Anderson Sam Goldblith Associate Professor Massachusetts Institute of Technology (MIT) Join the Discussion on SEARCH GROUPS FOR: CRISPR Precision Genome Editing to join the online community.
  4. 4. Conference Day One 8.00 Registration, Breakfast Networking 9.00 Chair’s Opening Remarks CRISPR the Superior: A Revolution That Speeds On 9.10 Keynote Interviews: Optimizing CRISPR Design to Efficiently Power Novel Applications in Drug Discovery, Screening and Therapeutic Development The panel will discuss and answer the following questions: • How has the novel CRISPR enzyme Cpf1 enhanced the application CRISPR technology? • With continued innovation - will CRISPR always be at the top or are there better alternatives emerging to drive gene engineering? • How has the industry tried to enhance CRISPR/Cas9 mediated gene- editing in primary cells? • How is the industry addressing the ethical challenges surrounding genetic editing of germline cells in order to be diligent whilst pushing scientific boundaries? • From a therapeutic perspective, how close are we to demonstrating clinical utility and what have been the lessons learning in preparing CRISPR-based gene therapies for human trials? Emmanuelle Charpentier, Director, Max Planck Institution for Infection Biology, MIMS, Umeå University Alexandra Glucksmann, Chief Operating Officer, Editas Medicine Rodger Novak, Chief Executive Officer, CRISPR Therapeutics Rachel Haurwitz, President CEO, Caribou Biosciences 10.00 Using CRISPR as a Screening Tool for Genomic Target Validation Screens and to Identify Novel Drug Targets • Learn to accurately analyze data from screens and to functionally validate them • Genome wide screening for gain of function or loss of function screening, either in exploring the developmental state for basic biology or for screening for therapeutic targets for diseases (drug development) • Discover how to establish CRISPR libraries for target identification Jon Moore, CSO, Horizon Discovery 10.30 Morning Refreshments Speed Networking Measuring and Optimizing Specificity of the CRISPR/Cas9 System 11.30 Keynote Presentation: The CRISPR-Cas9 Revolution in Genome Engineering: Lessons Learned from Bacteria • Addressing the origins of CRISPR-Cas9 • Discover the mechanisms of CRISPR-Cas9 and to highlight the evolution of CRISPR-Cas9 Emmanuelle Charpentier, Director, Max Planck Institution for Infection Biology, MIMS, Umeå University 12.15 Beyond Cas9: Discovering New Tools for Precision Genome Editing • Using smaller, easier to deliver Cas9 orthologs enables new translational applications for genome editing • Cas9 is just one of many programmable nucleases in nature with gene editing potential • The RNA-guided endonuclease Cpf1 expands the genome engineering toolbox and allows for allele-specific targeting Jonathan Gootenberg, Feng Zhang’s Lab, Harvard University 12.45 Ultra-Sensitive Quantification of Genome Editing Events by Droplet Digital PCR • Genome editing events can be rare and difficult to quantify, with frequencies 5% in some targeted cell types • Genome editing methods development and optimization would benefit from a sensitive, rapid-readout tool for edit validation and off-target detection • Droplet Digital PCR (ddPCR) enables sensitive (0.1%), precise absolute quantification of NHEJ and HDR alleles in a rapid, high- throughput format Jennifer Berman, Staff Scientist, Applications, Digital Biology Center, Bio-Rad Laboratories Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 Tuesday February 23rd 2016
  5. 5. 16.45 Breakout Roundtables: Advancing CRISPR Technology to The Next Level Discover multiple perspectives on the key issues and applications in the revolutionary CRISPR field by joining roundtable discussions, specifically designed so you can learn from your fellow gene-editing peers. Moderators: Joel Klappenbach, Director of Applied Genomics, Merck Jon Moore, CSO, Horizon Discovery Daniel Anderson, Sam Goldblith Associate Professor, Massachusetts Institute of Technology (MIT) Discovering how to perform high throughout genome screenings in the development of CRISPR libraries 5. Collaborating to develop and define protocols for gene editing in non- eukaryotic cells 4. Advancing non-viral delivery methods to progress CRISPR-therapeutics – how can you refine methodology to overcome this key hurdle of CRISPR therapeutic development in the context of clinical utility 3.Harnessing CRISPRi technology to fast-track development of therapies – ensuring sequence specific control of gene expression 2.Evaluating and combining different methods to enhance specificity of CRISPR to minimize unwanted off-target effects 1. 13.15 Networking Lunch 14.15 From “Gene Editing” to True Genome-Scale Engineering • Reducing issues with competing events like Non-Homologous End-Joining (NHEJ) and efficiency of large construct insertion/ replacements in homologous recombination editing • Overcoming NHEJ events with the use of a promising alternative to double-strand breaks (CRISPR, dual nickase or FokI) via recombinase/integrase mechanisms George Church, Professor of Genetics, Harvard Medical School 14.45 Genome Editing Solutions - New Workflow Tools for Genome Editing • High Efficiency editing in difficult cell lines using cas9 mRNA or RNPS • Improved delivery using Neon electroporation or Lipofectamine CRISPRMAX Jason Potter, Senior Scientist Manager, Thermo Fisher Scientific 15.15 How Epigenome Editing Can Be Used to Reprogram Cell Phenotype for Disease Modeling and Regenerative Medicine • Insight into how epigenome editing tools have been developed to perturb gene regulatory elements • Annotating the function of regulatory elements can be used to discover new drug targets, diagnostics, and strategies for personalized medicine Charles Gersbach, Associate Professor, Director, Center of Biomolecular Tissue Engineering, Duke University 15.45 Afternoon Refreshments Poster Session 16.15 Beyond the Break: Options for Donor-DNA Driven Genome Editing with High Fidelity and Efficiency • Donor DNA formats and their impact on DNA repair rates • Learn to manipulate DNA repair outcomes among diverse cell types • Strategies for pooled screens using CRISPR and donor-DNA libraries Gregory Davis, RD Manager, Molecular Biotechnology, Sigma-Aldrich 17.45 Chair’s Closing Remarks Jon Moore, CSO, Horizon Discovery 17.50 Evening Drinks Reception Hosted by Horizon Discovery Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016
  6. 6. Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 Conference Day Two 8.00 Breakfast Networking 9.00 Chair’s Opening Remarks Advancing Large Scale Genome Wide Screening 9.10 Harnessing the Power of CRISPR to Improve Drug Discovery Across Key Therapeutic Areas • Optimizing experimental design and data analysis to validate hits from the screens • Evaluating the genes to knock-out to eliminate expression of target gene and subsequent genes to build the have workout interactions Lorenz Mayr, VP Global Head, Reagents Assay Development, AstraZeneca 9.40 Innovative Trait Development Tools in Plant Breeding will be Crucial for Doubling Global Agricultural Productivity by 2050 • Rapid Trait Development System (RTDS™) employs Gene Repair OligoNucleobases (GRONs) to make defined spelling changes in genomic DNA • We report that RTDS can significantly improve the outcome of double strand break activity by reliably inducing precise and targeted nucleotide spelling changes closely aligned to the cut site • Our work demonstrates the significance of gene editing to rapidly, precisely and reliably improve cro performance to develop any trait in commercially relevant crop varieties Greg Gocal, Senior Vice President, Research Development, Cibus 10.10 Opportunities and Challenges of Applied Genome Engineering Technologies in the Pharmaceutical Research Setting • Genome engineering is advancing at an incredible pace however, applications across the types of translational and predicative cell models now preferred for drug target discovery remains a challenge • What areas of the drug discovery process will genome engineering have the biggest and most immediate impact • How does the pharmaceutical industry evaluate and implement a technology that is evolving so rapidly John Feder, Associate Director of Genome Biology, Bristol-Myers Squibb 10.40 Improving CRISPR-Cas9 Gene Knockout with a Validated Guide RNA Algorithm • Development of an algorithm for improved CRISPR RNA functionality and specificity • Utility of a synthetic two-RNA approach for high-throughput arrayed gene knockout • Importance of rigorous alignment tools for CRISPR RNA specificity Anja Smith, Director of RD, Dharmacon, GE Healthcare 11.10 Morning Refreshments 11.40 Understanding the Regulatory Requirements for CRISPR/ Cas9 Mediated Therapeutic Development • Addressing the safety aspects involving specificity and understanding the proper usage and safety concerns of different delivery techniques • Learnings from other gene editing tools in the clinic • WhatistheregulatorypathwayandhowequippedornotareEFSAandtheFDA • Addressing successful case studies involved in regulatory path of TALENs or ZFNs Alexandra Glucksmann, COO, Editas Medicine Wednesday February 24th 2016
  7. 7. Harnessing CRISPR Technology in Disease and Preclinical Modeling 12.10 Optimizing Bioinformatic Tools to Improve Guide Design and to Enhance Specificity • Optimize CRISPR/Cas systems to drive gene editing • Utilize CRISPR corrects the underlying disease-causing mutations • Harness bioinformatics and design strategies to improve and ensure specificity • Discovering the use of new CRISPR systems TJ Cradick, Head of Genome Editing, CRISPR Therapeutics 12.40 Tipping the CRISPR NHEJ/HDR Imbalance: Strategies for Efficient Generation of Large-Size-DNA Knock-in Animal Models • Latest developments in enhancing insertion of larger DNA molecules using HDR-dependent and HDR-independent mechanisms • The CRISPR strategies that help rapid development of humanized animal models Channabasavaiah Gurumurthy, Assistant Professor-Genetics, Director- Mouse Genome Engineering Core Facility, University of Nebraska Medical Center 13.10 Applying GenCRISPR Efficiently – Pioneering to Make Genome-Editing Easy • GenCRISPR services cover mammalian and bacterial cell line services • GenCRISPR-related reagents and making research easy through one-stop service solution Shawn Zhou, Senior Scientist, GenScript 13.20 Networking Lunch 14.20 Precision Cancer Mouse Models Through Genome Editing with CRISPR-Cas9 • Address how CRISPR can speed up the generation of precision cancer models • How these models can be used to understand the evolution and progression of individual tumors • Identify new strategies for cancer treatment Wen Xue, Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Medical School Maximizing Precision for Novel Applications 14.50 Increase Efficiency of Genome Editing Using the Alt-R™ CRISPR-Cas9 System • Improving on-target CRISPR-Cas9 genome editing performance while also reducing cell toxicity and eliminating innate cellular immune response as compared to in vitro transcribed guide RNA alternatives • A discussion on challenges and potential pitfalls of genome editing with guidance towards successful CRISPR-Cas9 editing experiments Mark Behlke, Chief Scientific Officer, Integrated DNA Technologies, Inc Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016
  8. 8. Is Cpf1 the start of the next generation class of CRISPR enzymes? What are the next exciting applications on the horizon? What are the fundamental next steps required to develop and optimize CRISPR technology further? 15.10 Application of CRISPR Technologies to Genetic Screens • As a powerful tool for large scale screens how do CRISPR libraries perform in actual screens? • What factors are experimentally shown to be important? • What are strengths and limitations of CRISPR libraries and screens? David Root, Senior Director, Broad Institute Genetic Perturbation Platform and the Functional Genomics Consortium 15.40 Afternoon Refreshments 16.10 Genetic Screens with CRISPR-Cas9: Optimizing On-Target Activity and Avoiding Off-Target Effects • Considerations for library design to optimize on-target activity • Detection and avoidance of potential off-target activity • Comparison of CRISPR to RNAi John Doench, Associate Director, Genetic Perturbation Platform, MIT, Harvard University   16.40 Expanding and Improving the Genome-Wide Specificities of CRISPR-Cas9 Nucleases • The targeting range of Cas9 can be expanded by engineering variants that can target previously inaccessible sitesDetection and avoidance of potential off-target activity • The genome-wide specificity of Cas9 can be improved with novel evolved variants • GUIDE-seq can be used to define the genome-wide specificities of Cas9 variants Benjamin Kleinstiver, Postdoctoral Fellow, Keith Joung’s Group, Massachusetts General Hospital Harvard Medical School 17.10 CRISPR Roundtable Intelligence Mastermind Discussion Missed a roundtable you wished you were at or have unanswered questions to your specific challenges? Roundtable moderators summarize the industry intelligence from the Day 1 Breakout Roundtables, providing you one final opportunity to outline key future trends for the CRISPR gene editing field. The panel will discuss the following: 17.25 Chair’s Closing Remarks 17.30 Evening Drinks Reception Hosted by Sigma-Aldrich Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016
  9. 9. Workshop A Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 CRISPR technology has rapidly changed the face of biological research. In particular, precision genome editing has been so readily adopted it has now become routine for many labs. One key application of CRISPR is in the discovery and functional understanding of genomics through high-throughput screening. In this interactive workshop, attendees will capitalize lessons learned in order to: • Develop protocols to carry out large scale genome screens to better understand gene interactions in disease • Learn from a range of applications to optimize the development of CRISPR libraries • Optimize data analysis of genome screens for target identification in drug discovery CRISPR/Cas9-mediated genome editing has become the preferred tool of choice when it comes to efficiently and easily manipulating the genome with strong specificity. As such, a rapidly adopted application has emerged to create more physiologically relevant and predictable in vivo disease models to better understand the complexity of human disease. In this interactive workshop, attendees will discover solutions and answers to help them: • Outline the latest in developments in the CRISPR-mediated generation of disease models • Overcome the current limitations of using CRISPR for disease modeling • Harness CRISPR gene editing technology to develop humanized animal models, particularly for emerging immunotherapies • Address and discuss case studies to standardize protocols to utilize CRISPR for in vivo models Performing High Throughout Genome Screenings for Developing CRISPR Libraries Date: Thursday February 25th 2016 | Time: 9.00am – 12.00pm Developing More Predictable Disease Models With CRISPR: From Basic Research to Target Identification and Drug Discovery Date: Thursday February 25th 2016 | Time: 1.00pm – 4.00pm TJ Cradick, PhD has studied the different families of nucleases that enable genome editing and gene therapy, such as for correcting mutations that cause diseases. Recent work has focused on CRISPR/Cas nucleases (see publication list). Previously we developed and studied TAL Effector Nucleases (TALENs), and Zinc Finger Nucleases (ZFNs). Many of these studies in academia or industry included measuring and improving specificity. TJ co-authored manuscripts detailing our bioinformatics web tools: ZFN-Site, PROGNOS, SAPTA and COSMID (CRISPR off-target).  Workshop Leader TJ Cradick, Head of Genome Editing, CRISPR Therapeutics CB Gurumurthy obtained a faculty position at the University of Nebraska Medical Center (UNMC), Omaha in 2007. He is currently an assistant professor in Developmental Neuroscience Department and serves as the Director of UNMC Mouse Genome Engineering Core Facility. He is actively pursuing research in developing newer geneome editing technologies in addition to developing widely-usable animal models for basic and drug discovery research. Workshop Leader Channabasavaiah Gurumurthy, Assistant Professor-Genetics, Director- Mouse Genome Engineering Core Facility, University of Nebraska Medical Center Workshop B
  10. 10. CRISPR Partners Sigma-Aldrich Sigma-Aldrich is proud to offer its newest line of genome editing tools, Sigma CRISPRs, to the global research community. Sigma CRISPRs offer rapid, reliable and reproducible results – everything you need for gene editing experiments. Sigma-Aldrich also offers the CRISPR Core Partnership Program providing scientists and core facilities with world class service and a diverse portfolio of innovative CRISPR reagents, with the support of an industry-leading bioinformatics engine. The Cell Design Studio team at Sigma Aldrich, utilizes CRISPR, ZFN, and shRNA technologies to rapidly and efficiently generate model cell lines to be used in basic research, cell- based assays, target validation and much more. www.sigmaaldrich.com Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life Sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. www.thermoscientific.com Program Partner Program Partner Bio-Rad Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics. www.bio-rad.com Program Partner Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 Horizon Discovery Horizon Discovery combines long scientific heritage in translational research with GENESIS™, a precision gene editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organisations. www.horizondiscovery.com Lead Partner
  11. 11. CRISPR Partners Dharmacon – part of GE Healthcare Dharmacon has revolutionized the field of RNA synthesis with the introduction of 2’-ACE synthesis chemistry since 1995. As leaders in custom RNA synthesis, Dharmacon was an early participant in the newly discovered field of RNA interference, and contributed several key scientific findings. Dharmacon RNAi products were some of the first commercially available. This leadership has continued through technical advances in bioinformatics, and chemical modifications to improve performance. Today, our areas of research and research tools have expanded to support all aspects of RNAi interference; siRNA, lentiviral shRNA, tools for microRNA research, and whole-genome scale libraries for RNAi functional screens of genes, microRNAs and long non-coding RNAs. Dharmacon also has the largest collection of cDNAs and ORFs commercially available. In addition, Dharmacon offers a unique set of CRISPR-Cas9 gene editing tools. The Dharmacon CRISPR-Cas9 platform greatly simplifies the workflow of permanently knocking out genes. Our approach includes pre- designed, ready-to-use DNA and RNA components and enables fast assessment of multiple target sites per gene for multiple genes. We offer CRISPR Guide RNA, high quality, ready-to-use lentiviral and synthetic reagents to guide Cas9 cleavage;  Cas9 Nuclease for your cell type to ensure robust Cas9 expression or explore DNA-free options; CRISPR Controls and Detection Primers essential to assessment of CRISPR-Cas9 genomic editing experiments; CRISPR-Cas9 Pooled sgRNA or arrayed crRNA for high-throughput gene editing studies. www.dharmacon.gelifesciences.com Program Partner Cibus Cibus has developed plant and microbial platforms enabling it to become a world leader in precision gene editing, generally, and advanced non-transgenic breeding, specifically. The Rapid Trait Development System (RTDS™), its proprietary technology for non-transgenic breeding, enables site-specific edits of native genes with no introduction of foreign DNA. The precise and predictable outcomes can replicate products developed using traditional mutagenesis and are identical to those that could occur in nature, given enough time. Consequently, these plants are not considered transgenic, the key attributes of GMO crops. www.cibus.com Program Partner Integrated DNA Technologies Integrated DNA Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. The largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development. IDT products support a wide variety of applications, including next generation sequencing (NGS), genome editing, DNA amplification, SNP detection, microarray analysis, expression profiling, gene quantification, and synthetic biology. Platform-independent NGS products and services are available in addition to DNA and RNA oligonucleotides, qPCR assays, siRNA duplexes, reagents for CRISPR-Cas9 genome editing, and custom gene synthesis services. IDT has an active research and development division that supports product development, and participates in corporate and academic collaborations. IDT also supports the education of the next generation of scientists through our regular sponsorship of the international Genetically Engineered Machine (iGEM) competition, and other scientific outreach activities. www.idtdna.com Program Partner Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016
  12. 12. Contact Diane McKenna Portfolio Director, Genomics Tel: +44 (0)203 141 8700 Email: sponsor@hansonwade.com Join The CRISPR Partnership: Advanced Analytical Technologies Advanced Analytical Technologies, Inc. (AATI), founded in 1998 and located in Ankeny, Iowa, is a world leader in multi-channel (parallel) capillary electrophoresis. The company’s products are designed to improve processes within the life science, agricultural, molecular diagnostics, biofuels, biotechnology, and pharmaceutical industries. Its award winning instrument, the Fragment Analyzer™ is the premier instrument to automate the analysis of nucleic acid fragments and smears. Designed to improve laboratory workflow and decrease time to results, the Fragment Analyzer can dependably and reliably assess gene editing events generated through CRISPR/Cas9 mutagenesis using a streamlined heteroduplexing and cleavage process for ultra-sensitive detection of fragments and digital data outputs with specially designed software to aid in analysis. Additionally, Reagent Kits are available to accurately qualify and quantify nucleic acid raw materials like genomic DNA and RNA and analyze NGS library preparation. The Fragment Analyzer is the premier instrument to automate analysis of nucleic acids. www.aati-us.com Exhibitor GenScript GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading Contract Research Organization that provides services and products to scientists in 86 countries worldwide www.genscript.com Spotlight Partner CRISPR Partners Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 The CRISPR Congress was highly successful...a very engaging meeting Bio-Rad on CRISPR Congress 2015
  13. 13. Code:5792 * All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time. Changes to Conference Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU Hanson Wade Limited. Registered in England Wales. Company No: 6752216 Terms Conditions Register Event Prices Pricing Venue Hyatt Regency Boston One Avenue de Lafayette Boston, Massachusetts, USA, 02111 Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering. Academic Not-for-Profit Pricing Package Register Pay before Friday November 13th 2015 Register Pay before Friday December 18th 2015 Register Pay before Friday January 22nd 2016 Standard Prices Gold Package: Conference + 2 Workshops $1897 (save $700) $2097 (save $500) $2297 (save $300) $2397 (save $200) Silver Package: Conference + 1 Workshop $1498 (save $600) $1698 (save $400) $1898 (save $200) $1998 (save $100) Bronze Package: Conference Only $1099 (save $500) $1299 (save $300) $1499 (save $100) $1599 Workshop Each: $499 Industry Pricing Package Register Pay before Friday November 13th 2015 Register Pay before Friday December 18th 2015 Register Pay before Friday January 22nd 2016 Standard Prices Gold Package: Conference + 2 Workshops $3297 (save $800) $3497 (save $600) $3697 (save $400) $3797 (save $300) Silver Package: Conference + 1 Workshop $2698 (save $700) $2898 (save $500) $3098 (save $300) $3198 (save $200) Bronze Package: Conference Only $2099 (save $600) $2299 (save $400) $2499 (save $200) $2699 Workshop Each: $699 Tel: +1 212 537 5898 Email: info@hansonwade.com crispr-congress.com #CRISPR2016 CRISPR Precision Genome Editing 2nd Annual CRISPR Precision Gene Editing Congress Boston, USA | February 23-25 2016 • 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team Discounts* crispr-congress.com/register Tel: +1 212 537 5898 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

×